Gene Therapy-Directed Apoptosis and Cell Control
Apoptosis is a programmed cell death process, strictly controlled by genes, with characteristic morphological and biochemical changes. Apoptosis plays an important role in development, tissue homeostasis, immune regulation and disease occurrence. Abnormal or dysregulated apoptosis is closely related to the occurrence and development of various diseases, especially cancer. Therefore, modulation of apoptosis is a potential therapeutic strategy to prevent or treat disease by eliminating abnormal or damaged cells.
Gene therapy refers to the introduction of exogenous normal or modified genes into target cells to correct or compensate for diseases caused by defective and abnormal genes so as to achieve therapeutic purposes. Gene therapy can target apoptosis or cell control through different methods and strategies to regulate cell survival, proliferation, differentiation, and death. Cell control refers to a group of molecular mechanisms that regulate cell cycle progression, DNA damage response, and epigenetic modification to ensure the normal execution of cell functions and the stable transmission of genetic information. Modulating cellular control is therefore another potential therapeutic strategy to prevent or treat disease by repairing or enhancing cellular function. The significance of gene therapy-directed apoptosis and cell control is that it can restore or improve the normal state of cells by precisely regulating the expression or activity of specific genes so as to achieve therapeutic purposes. Gene therapy-directed apoptosis and cell control can select appropriate methods and strategies for different types and stages of diseases to induce or inhibit apoptosis or cell control so as to inhibit tumor growth, clear infected or damaged cells, and restore organizational functions. Gene therapy can target apoptosis or cell control through different methods and strategies, thereby regulating cell survival, proliferation, differentiation, and death. Over the past few decades, gene therapy-directed apoptosis and cellular control have made significant progress in the treatment of previously untreatable inherited or acquired diseases.
Methods and Strategies for Gene Therapy-Directed Apoptosis and Cell Control
The methods and strategies of gene therapy-directed apoptosis and cell control can be applied to various types of diseases, such as cancer, genetic diseases, infectious diseases, and so on. In cancer therapy, the methods and strategies of gene therapy-directed apoptosis and cell control mainly achieve the purpose of inhibiting tumor growth by inducing apoptosis of cancer cells or inhibiting their proliferation. For example, transduction of the normal p53 gene can restore the tumor suppressor function of the p53 protein and induce apoptosis in cancer cells. Transduction of siRNA or shRNA can silence the Bcl-2 gene and induce apoptosis of cancer cells. Transduction of the caspase-3 enzyme can activate the caspase cascade reaction and induce cancer cell apoptosis. Transduction of TRAIL ligand can activate the death receptor signaling pathway and induce cancer cell apoptosis. Transduction of miRNA or lncRNA can interfere with the Ras gene and inhibit cancer cell proliferation. In the treatment of genetic diseases, the methods and strategies of gene therapy directed at apoptosis and cell control mainly achieve the purpose of curing or relieving symptoms by restoring or improving damaged or missing gene functions. For example, transduction of a normal or modified hemoglobin gene can restore normal hemoglobin function and treat thalassemia. Transduction of a normal or modified CFTR gene can restore normal CFTR function and treat cystic fibrosis. Transduction of a normal or modified DMD gene can restore normal DMD function and treat Duchenne muscular dystrophy. In the treatment of infectious diseases, the method and strategy of gene therapy-directed apoptosis and cell control mainly achieve the purpose of eliminating or controlling infection by clearing infected or damaged cells or enhancing the function of the immune system. For example, transduction of specific nucleic acid molecules can silence or interfere with HIV genes and eliminate HIV-infected CD4+ T cells. Transduction of specific enzymes or ligands can activate or inhibit specific signaling pathways to enhance the clearance of immune cells against infections such as HBV or HCV.
Methods and strategies for gene therapy-directed apoptosis and cell control have some common advantages and disadvantages, opportunities and challenges, and also some individual characteristics. The main benefit of both gene therapy-directed apoptosis and cell control is that they can control the expression or activity of specific genes in a way that is therapeutically useful. It is also possible to select appropriate methods and strategies for different types and stages of diseases so as to achieve the best results. They can also be used in combination with other treatments, such as chemotherapy, radiotherapy, and immunotherapy, to enhance the therapeutic effect or reduce side effects. The main problem is that methods and strategies for gene therapy-directed apoptosis and cell control need to solve a number of technical and safety issues, such as carrier selection and optimization, improvement of targeting and efficiency, immune response, and toxic side effects. It is necessary to consider the effects of gene therapy-directed apoptosis and cell control methods and strategies on normal cells or tissues, such as whether they will cause non-specific or excessive apoptosis or cell control, resulting in tissue damage or dysfunction. Gene therapy methods and strategies for directed apoptosis and cellular control can be used to treat many types of diseases, especially inherited or acquired diseases that were previously incurable or in remission, like cancer, thalassemia, and Duchenne muscular dystrophy. Emerging technologies and platforms, such as the CRISPR-Cas system, mRNA technology, and artificial intelligence, can be used to improve the accuracy, efficiency, and safety of methods and strategies for gene therapy-directed apoptosis and cell control. A common challenge is that the methods and strategies of gene therapy-directed apoptosis and cell control need to face strict regulations and ethical issues, such as whether they will affect the integrity, stability, and diversity of the human genome, whether they will cause public or Patient group concerns or objections, or whether they will lead to an unfair or unequal distribution of medical resources.
Table 1. Respective Features of Methods and Strategies for Gene Therapy Directed Apoptosis and Cell Control
| Method and strategy | Advantages | Disadvantages |
|---|---|---|
| Transducing normal or modified genes to restore or enhance the function of apoptosis- or cell control-related proteins |
- Can directly restore or improve the impaired or missing gene function, thus achieving the therapeutic goal. - Can use known normal or modified genes as exogenous genes, thus reducing uncertainty and risk. - Can use viral or non-viral vectors to deliver exogenous genes into target cells, thus improving efficiency and stability. |
- May cause immune response or toxic side effects, such as inflammation, fever, swelling, etc. - May cause random integration or loss of exogenous genes, thus affecting expression level or persistence. - May cause mutation or recombination of exogenous genes, thus affecting function or safety. |
| Transducing specific nucleic acid molecules to silence or interfere with abnormal or overexpressed genes, thus inducing or inhibiting apoptosis or cell control |
- Can precisely silence or interfere with specific genes, thus achieving the therapeutic goal. - Can use various types of nucleic acid molecules, such as siRNA, shRNA, miRNA, lncRNA, etc., thus increasing selectivity and flexibility. - Can use non-viral vectors to deliver nucleic acid molecules into target cells, thus reducing immune response and toxic side effects. |
- May cause non-specific or excessive gene silencing or interference, thus affecting normal cell or tissue function. - May cause instability or degradation of nucleic acid molecules, thus affecting efficacy or persistence. - May cause insufficient targeting or efficiency of nucleic acid molecules, thus affecting therapeutic outcome. |
| Transducing specific enzymes or ligands to activate or inhibit specific signaling pathways, thus regulating apoptosis or cell control |
- Can directly manipulate specific signaling pathways, thus achieving the therapeutic goal. - Can use known enzymes or ligands as exogenous molecules, thus reducing uncertainty and risk. - Can use viral or non-viral vectors to deliver exogenous molecules into target cells, thus improving efficiency and stability. |
- May cause immune response or toxic side effects, such as inflammation, fever, swelling, etc. - May cause random integration or loss of exogenous molecules, thus affecting expression level or persistence. - May cause mutation or recombination of exogenous molecules, thus affecting function or safety. |
In summary, the method and strategy of gene therapy-directed apoptosis and cell control are promising treatment methods that can provide precise, effective, and safe treatment options for various types of diseases. However, it also faces multiple technical and security challenges, as well as regulatory and ethical pressures. Therefore, continuous scientific research and technological innovation are needed to overcome these difficulties and challenges. At the same time, it is also necessary to strengthen the education and communication of the public and patient groups to increase awareness and acceptance of the methods and strategies of gene therapy for targeting apoptosis and cell control.
Advances in Clinical Research of Gene Therapy-Directed Apoptosis and Cell Control
The clinical trial of gene therapy-directed apoptosis and cell control is a method that uses genes or gene carriers to induce tumor cell apoptosis or inhibit tumor cell proliferation so as to achieve the purpose of anti-cancer. This method mainly targets some common tumor-related genes, such as p53, Bcl-2, and E2F-1, or uses gene editing technology, such as the CRISPR-Cas system, to repair or change the gene expression or function of tumor cells.
According to the search results of the clinical trial database ClinicalTrials.gov, as of April 30, 2023, there are 136 clinical trials related to gene therapy-directed apoptosis and cell control in the world, of which 72 have been completed and 54 are in progress. 10 were terminated or withdrawn. These clinical trials involve various types of tumors, such as head and neck squamous cell carcinoma, liver cancer, breast cancer, prostate cancer, ovarian cancer, gastric cancer, colorectal cancer, lung cancer, melanoma, lymphoma, etc. These clinical trials are mainly distributed in the United States, China, Europe, and Japan.
The clinical trials of gene therapy-directed apoptosis and cell control mainly include the following types:
- Gene transfer: Introduce exogenous genes into tumor cells or normal cells through viral or non-viral vectors to express proteins that promote apoptosis or inhibit proliferation, such as p53 and E2F-1.
- Gene knockout: Through gene editing technology, such as the CRISPR-Cas system, a certain gene in tumor cells is completely or partially deleted to make it lose its function, such as Bcl-2, etc.
- Gene correction: Using gene editing technology, such as the CRISPR-Cas system, to restore a mutated gene in tumor cells to a normal sequence and restore its function, such as p53, etc.
- Gene regulation: Interfering with the expression or activity of a certain gene in tumor cells by antisense nucleic acid, small interfering RNA, single-chain antibody, etc., to down-regulate or inactivate it, such as Bcl-2, etc.
The results of clinical trials of gene therapy-directed apoptosis and cell control show that this method has certain safety and efficacy in some tumor types, can enhance the sensitivity of tumor cells to chemotherapy or radiotherapy, and can induce tumor cell apoptosis. Death. However, this method also has some limitations and challenges, such as low gene transfer efficiency, low precision of gene editing, an immune response, and toxic side effects. At present, no method of gene therapy-directed apoptosis and cell control has been officially approved for marketing, and more clinical trials and data are still needed to prove its safety and efficacy.
The following are some representative or innovative clinical trials:
- Using the p53 gene to treat head and neck squamous cell carcinoma: a method of using the p53 gene or gene carrier to restore the function of p53 in tumor cells, thereby inducing the apoptosis of tumor cells or enhancing the sensitivity of tumor cells to chemotherapy or radiotherapy At present, several clinical trials are ongoing or completed, such as those for Ad-p53, Gendicine, and SGT-53. The results show that this method has certain safety and efficacy characteristics, but more data are still needed to support its clinical application.
- Using the E2F-1 gene to treat liver cancer: a method of using the E2F-1 gene or gene carrier to activate the E2F-1 transcription factor in tumor cells, thereby inducing tumor cell apoptosis or inhibiting tumor cell proliferation. Currently, a phase I clinical trial is underway (NCT02451023), recruiting Chinese patients with primary liver cancer and comparing the effect of the E2F-1 gene combined with radiotherapy and chemotherapy with radiotherapy and chemotherapy alone.
- Using the CRISPR-Cas system to edit genes to treat blood system diseases: a way of using the CRISPR-Cas system to repair or change the sequence or function of a certain gene in blood cells, thereby treating some inherited or acquired blood system diseases, such as β-thalassemia, sickle cell anemia, leukemia, and so on. Currently, several clinical trials are ongoing or completed, such as CTX001, CTX110, and CTX120. The results show that this method has innovation and potential, but some technical and ethical difficulties still need to be overcome.
References
- Ullrich E, et al. Mitochondrial apoptosis: facilitator of NK cell-mediated immunotherapy. Signal Transduct Target Ther. 2022 Aug 18;7(1):291.
- Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011 Sep 26;30(1):87.
- Weidemüller P, et al. Transcription factors: Bridge between cell signaling and gene regulation. Proteomics. 2021 Dec;21(23-24):e2000034.
- Jia LT, et al. Cancer gene therapy targeting cellular apoptosis machinery. Cancer Treat Rev. 2012 Nov;38(7):868-76.
- Maguire CA, et al. Gene therapy for the nervous system: challenges and new strategies. Neurotherapeutics. 2014 Oct;11(4):817-39.
- Duffy MJ, et al. Targeting p53 for the treatment of cancer. Semin Cancer Biol. 2022 Feb;79:58-67.
- Perri F, et al. p53 mutations are the only common genetic events in head and neck cancer patients with HPV-negative and tobacco exposure. Oncotarget. 2017;8(13):21727-21738.
- Duffy MJ, et al. Targeting p53 for the treatment of cancer. Semin Cancer Biol. 2022 Feb;79:58-67.
- Nemunaitis J, et al. Biomarkers predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck. Clin Cancer Res. 2009;15(23):7719-7725.
- Liang X, et al. Phase I trial of intratumoral injection of recombinant human endostatin adenoviruses in combination with radiotherapy in patients with locally advanced hepatocellular carcinoma. Int J Cancer. 2014;134(4):903-911.
